Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 321 to 330 of 899

TitleReference numberPublishedLast updated
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Upadacitinib for treating active ankylosing spondylitisTA829
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826

Results per page

  1. 10
  2. 25
  3. 50
  4. All